Samsung Group said Tuesday its near-replica of Johnson & Johnson’s blockbuster arthritis drug Remicade has been accepted for review by the U.S.
Samsung Group said Tuesday its near-replica of Johnson & Johnson’s blockbuster arthritis drug Remicade has been accepted for review by the U.S.